News / 08 Oct 2021
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors
News / 30 Sep 2021
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
News / 11 Aug 2021
Summit Therapeutics Provides Update on Ri-CoDIFy Trials
We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike.
Chairman & Chief Executive Officer